Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;24(4):428-436.
doi: 10.22038/IJBMS.2021.48628.11161.

An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020)

Farzad Khademi  1 , Amirhossein Sahebkar  2   3   4
Affiliations
Review

An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020)

Farzad Khademi et al. Iran J Basic Med Sci. 2021 Apr.

Abstract

This updated systematic review and meta-analysis follows two aims: 1) to assess Mycobacterium tuberculosis (M. tuberculosis) antibiotic resistance in Iran from 2013 to 2020 and, 2) to assess the trend of resistance from 1999 to 2020. Several national and international databases were systematically searched through MeSH extracted keywords to identify 41 published studies addressing drug-resistant M. tuberculosis in Iran. Meta-analysis was done based on the PRISMA protocols using Comprehensive Meta-Analysis software. The average prevalence of resistance to first- and second-line anti-TB drugs, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in new and previously treated tuberculosis (TB) cases in Iran during 2013-2020 were as follows: isoniazid 6.9%, rifampin 7.9%, ethambutol 5.7%, pyrazinamide 20.4%, para-aminosalicylic acid 4.6%, capreomycin 1.7%, cycloserine 1.8%, ethionamide 11.3%, ofloxacin 1.5%, kanamycin 3.8%, amikacin 2.2%, MDR-TB 6.3% and XDR-TB 0.9%. Based on the presented data, M. tuberculosis resistance to first- and second-line anti-TB drugs, as well as MDR-TB, was low during 2013-2020 in Iran. Furthermore, there was a declining trend in TB drug resistance from 1999 to 2020. Hence, to maintain the current decreasing trend and to control and eliminate TB infection in Iran, continuous monitoring of resistance patterns is recommended.

Keywords: Antibiotic; Iran; Meta-analysis; Mycobacterium tuberculosis; Resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the literature search and study selection in the meta-analysis
Figure 2
Figure 2
Antimicrobial resistance trends of Mycobacterium tuberculosis strains to isoniazid, rifampin, ethambutol, streptomycin, as well as MDR-TB, among new and previously treated cases in Iran from 1999 to 2020
Figure 3
Figure 3
Forest plot (a) and funnel plot (b) showing streptomycin-resistant Mycobacterium tuberculosis prevalence among new and previously treated cases between 2013 and 2020 in Iran
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis report 2019. Gevena [Switzerland]: World Health Organization; 2019.
    1. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 8th ed. UK: Elsevier Health Sciences: 2015. pp. 221–225.
    1. Carroll KC, Butel JS, Morse SA. Jawetz Melnick & Adelbergs medical microbiology. 27th ed. Pennsylvania: McGraw Hill Professional; 2016. pp. 309–317.
    1. Khademi F, Taheri RA, Avarvand AY, Vaez H, Momtazi-Borojeni AA, Soleimanpour S. Are chitosan natural polymers suitable as adjuvant/delivery system for anti-tuberculosis vaccines? Microb Pathog. 2018;121:218–223. - PubMed
    1. Khademi F, Yousefi-Avarvand A, Derakhshan M, Najafi A, Tafaghodi M. Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration. Iran J Basic Med Sci. 2019;22:893–900. - PMC - PubMed

LinkOut - more resources